Profile
Kenneth Kobayashi served as Chairman of the Dermatology Division at The Ottawa Hospital, Medical Director at Novartis (Singapore) Pte Ltd., Senior Medical Director at Dermira, Inc., Associate Professor at the University of Ottawa, and Chief Medical Officer at Aslan Pharmaceuticals Ltd. He holds a doctorate degree from the University of British Columbia.
Former positions of Kenneth Kobayashi
| Companies | Position | End |
|---|---|---|
The Ottawa Hospital
The Ottawa Hospital Hospital/Nursing ManagementHealth Services Operates hospital | Corporate Officer/Principal | - |
University of Ottawa
University of Ottawa Other Consumer ServicesConsumer Services Functions as a College/University | Corporate Officer/Principal | - |
| DERMIRA, INC. | Chief Tech/Sci/R&D Officer | - |
Novartis (Singapore) Pte Ltd.
Novartis (Singapore) Pte Ltd. BiotechnologyHealth Technology Manufactures biological products | Chief Tech/Sci/R&D Officer | - |
| ASLAN PHARMACEUTICALS LIMITED | Chief Tech/Sci/R&D Officer | - |
Training of Kenneth Kobayashi
Experiences
Positions held
Active
Inactive
Listed companies
Private companies
Linked companies
| Private companies | 6 |
|---|---|
University of British Columbia
University of British Columbia Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
University of Ottawa
University of Ottawa Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
The Ottawa Hospital
The Ottawa Hospital Hospital/Nursing ManagementHealth Services Operates hospital | Health Services |
Novartis (Singapore) Pte Ltd.
Novartis (Singapore) Pte Ltd. BiotechnologyHealth Technology Manufactures biological products | Health Technology |
Dermira, Inc.
Dermira, Inc. Pharmaceuticals: MajorHealth Technology Manufactures pharmaceutical products to patients living with chronic skin conditions | Health Technology |
Aslan Pharmaceuticals Ltd.
Aslan Pharmaceuticals Ltd. BiotechnologyHealth Technology Operates as biotechnology company which develops immuno-oncology agents and targeted therapies | Health Technology |
- Stock Market
- Insiders
- Kenneth Kobayashi
















